Literature DB >> 7769304

Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene.

M A Egan1, W A Pavlat, J Tartaglia, E Paoletti, K J Weinhold, M L Clements, R F Siliciano.   

Abstract

CD8+ cytolytic T lymphocytes (CTL) are likely to be an important component of effective vaccines against human immunodeficiency virus type 1 (HIV-1). CTL can be induced most effectively with live virus vectors. However, because of concerns about the safety of such vectors, a nonreplicating canarypox vector (ALVAC) capable of expressing foreign genes in mammalian cells has been developed. This study evaluated the capacity of an ALVAC vector expressing the HIV-1MN envelope (env) glycoprotein to induce HIV-1-specific CTL in seronegative volunteers. Protocols were designed to determine whether immunization with ALVAC alone or in combination with subunit boosting could induce CTL in vaccinia-immune and -naive volunteers. A simple method for antigen-specific in vitro stimulation was used to detect CTL responses in HIV-1-seronegative vaccine recipients. The results indicate that low doses of a nonreplicating virus vector alone can elicit both CD4+ and CD8+ HIV-1-specific CTL in a subset of seronegative volunteers.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7769304     DOI: 10.1093/infdis/171.6.1623

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  23 in total

Review 1.  Nucleic acid vaccines: tasks and tactics.

Authors:  B S McKenzie; A J Corbett; J L Brady; C M Dyer; R A Strugnell; S J Kent; D R Kramer; J S Boyle; A M Lew
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 2.  Non-replicating expression vectors: applications in vaccine development and gene therapy.

Authors:  K J Limbach; E Paoletti
Journal:  Epidemiol Infect       Date:  1996-06       Impact factor: 2.451

3.  Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers.

Authors:  G Ferrari; W Humphrey; M J McElrath; J L Excler; A M Duliege; M L Clements; L C Corey; D P Bolognesi; K J Weinhold
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

4.  A Bivalent, Chimeric Rabies Virus Expressing Simian Immunodeficiency Virus Envelope Induces Multifunctional Antibody Responses.

Authors:  Amber Dunkel; Shixue Shen; Celia C LaBranche; David Montefiori; James P McGettigan
Journal:  AIDS Res Hum Retroviruses       Date:  2015-05-05       Impact factor: 2.205

Review 5.  Poxvirus vectors as HIV/AIDS vaccines in humans.

Authors:  Carmen Elena Gómez; Beatriz Perdiguero; Juan Garcia-Arriaza; Mariano Esteban
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

6.  Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants.

Authors:  Sharon E Frey; Laurence Peiperl; M Juliana McElrath; Spyros Kalams; Paul A Goepfert; Michael C Keefer; Lindsey R Baden; Michelle A Lally; Kenneth Mayer; William A Blattner; Clayton D Harro; Scott M Hammer; Geoffrey J Gorse; John Hural; Georgia D Tomaras; Yves Levy; Peter Gilbert; Allan deCamp; Nina D Russell; Marnie Elizaga; Mary Allen; Lawrence Corey
Journal:  Clin Vaccine Immunol       Date:  2014-09-24

7.  HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial.

Authors:  Pierre-Alexandre Bart; Yunda Huang; Shelly T Karuna; Samuel Chappuis; Julien Gaillard; Nidhi Kochar; Xiaoying Shen; Mary A Allen; Song Ding; John Hural; Hua-Xin Liao; Barton F Haynes; Barney S Graham; Peter B Gilbert; M Juliana McElrath; David C Montefiori; Georgia D Tomaras; Giuseppe Pantaleo; Nicole Frahm
Journal:  J Clin Invest       Date:  2014-10-01       Impact factor: 14.808

Review 8.  Applications of pox virus vectors to vaccination: an update.

Authors:  E Paoletti
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

9.  Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses.

Authors:  Sampa Santra; Dan H Barouch; Birgit Korioth-Schmitz; Carol I Lord; Georgia R Krivulka; Faye Yu; Margaret H Beddall; Darci A Gorgone; Michelle A Lifton; Ayako Miura; Valerie Philippon; Kelledy Manson; Phillip D Markham; John Parrish; Marcelo J Kuroda; Jörn E Schmitz; Rebecca S Gelman; John W Shiver; David C Montefiori; Dennis Panicali; Norman L Letvin
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-16       Impact factor: 11.205

10.  Prime-boost vaccination with recombinant mumps virus and recombinant vesicular stomatitis virus vectors elicits an enhanced human immunodeficiency virus type 1 Gag-specific cellular immune response in rhesus macaques.

Authors:  R Xu; F Nasar; S Megati; A Luckay; M Lee; S A Udem; J H Eldridge; M A Egan; E Emini; D K Clarke
Journal:  J Virol       Date:  2009-07-22       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.